Person: ERMERAK, NEZİH ONUR
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ERMERAK
First Name
NEZİH ONUR
Name
33 results
Search Results
Now showing 1 - 10 of 33
Publication Metadata only Kist hidatik'i taklit eden silyalı mukodüller papiller tümör(2023-10-19) ERMERAK, NEZİH ONUR; YILDIZELİ, BEDRETTİN; Ertan R., ASLAN S., ERMERAK N. O., YILDIZELİ B.Publication Metadata only Histopathological evaluation of post-mortem pulmonary specimens excised from ICU patients with COVID-19: Do we know what we do not know(2023-05-06) ERMERAK, NEZİH ONUR; BOZKURTLAR, EMİNE; KOCAKAYA, DERYA; GÜL, FETHİ; KARAKURT, SAİT; ERMERAK N. O., BOZKURTLAR E., KOCAKAYA D., GÜL F., KARAKURT S., Cinel I.Publication Open Access Esophageal perforation during intragastric balloon therapy: management of a patient with late referral(2023-01-01) ERMERAK, NEZİH ONUR; UPRAK, TEVFİK KIVILCIM; LAÇİN, TUNÇ; YILDIZELİ, BEDRETTİN; YEGEN, ŞEVKET CUMHUR; ERMERAK N. O., Uprak K. T., Emran M., LAÇİN T., YILDIZELİ B., YEGEN Ş. C.Minimally invasive treatment modalities like intragastric balloon therapy (IBT) gained popularity in the treatment of obesity [1]. Some morbidities have been reported in the literature, but it is limited. Esophageal perforation is the most feared complication of the procedure. Although endoscopic stent placement can be chosen as a treatment option in stable patients, most of the patients are treated with surgical drainage and primary repair [2]. We report an unusual case of intragastric balloon placement complicated with esophageal perforation which was successfully treated with a surgical approach after late referral.Publication Metadata only Treatment of pectus excavatum(Akademisyen Yayınevi, 2021-01-01) ERMERAK, NEZİH ONUR; YÜKSEL M., ERMERAK N. O.Publication Metadata only 18 years of experience in Minimally Invasive Pectus Surgery: Bar Removal(2022-09-14) ERMERAK, NEZİH ONUR; LAÇİN, TUNÇ; ERMERAK N. O., ASLAN S., YAMANSAVCI ŞİRZAİ E., LAÇİN T., YÜKSEL M.Publication Open Access Clinical validation of an activity-based enzyme assay for early stage lung cancer(2023-06-02) ERMERAK, NEZİH ONUR; Dempsey P., Sandu Aparacio C., Gonzalezirias R., Hantula S., Kagawa M., Bossmann S. H., Covarrubias-Zambrano O., Nagji A. S., Veeramachaneni N. K., ERMERAK N. O., et al.Background: The USPSTF guidelines recommend annual LDCT scans for 15.5 million adults with a heavy smoking history. While LDCT can reduce deaths by 20%, screening compliance remains low. A blood test with clinically useful, cost effective performance could improve compliance and access when integrated with the standard of care. We describe here a lyophilized nanosensor system for detecting protease enzyme activity in sera with clinically useful diagnostic activity in early stage lung cancer. We evaluated the performance of the assay by examination of prospectively collected sera for detection of cancer in high risk patients. Methods: Sera were obtained in multiple independent studies to include pathologically confirmed, treatment naive lung cancer patients and LDCT confirmed negative individuals. Protease activity was measured on 18 different nanosensors built with protease targets mainly selective for members of the Matrix Metalloproteinase and Cathepsin families. Lyophilized plates were incubated with serum and enzyme activity was measured indirectly as a continuous variable by a fluorescent plate reader. A machine learning modeling tool (Emerge) was used to detect signal associated with a cancer “fingerprint” of protease activity. The analysis stratified allocation into training and testing sets of 250 samples each and reserved a third out of sample validation set (250 samples) for reporting. Results: 750 clinical samples included 30% lung cancers, 63% males, 91% smokers, and an average age of 63 years (SD=9). Cancer cases were distributed across stages I (41%), II (17%), III (20%) and IV (20%) with 5% unknown. Histological classification included 59% adenocarcinoma, 31% squamous cell and 11% other subtypes. Using an Emerge model with only nanosensor activity and gender as inputs, we evolved a balanced algorithm. The algorithm can be further modified to favor sensitivity or specificity depending on the application by applying model weighting factors. We report the performance observed in the 250 out of sample validation set at three points on this spectrum (Table). Among Stage I cancer samples, the balanced algorithm had an accuracy of 90% (26/29). Conclusions: Current LDCT tools show low compliance. We demonstrate clinical validity of a cost effective tool to detect lung cancer in support of LDCT screening. Based on a simple blood sample, the current test may predict early stage lung cancer with an accuracy of 90%. The performance suggests applications in LDCT compliance, post LDCT management, and eventually screening. A clinically validated version of this technology is being evaluated as a triage tool for LDCT screening.Publication Open Access The angiogenic gene profile of pulmonary endarterectomy specimens: Initial study(2023-01-01) ERMERAK, NEZİH ONUR; YILMAZ, BETÜL; BATIREL, SAİME; OLGUN YILDIZELİ, ŞEHNAZ; KOCAKAYA, DERYA; MUTLU, BÜLENT; YILDIZELİ, BEDRETTİN; ERMERAK N. O., YILMAZ B., BATIREL S., OLGUN YILDIZELİ Ş., KOCAKAYA D., MUTLU B., Tas S., YILDIZELİ B.© 2023 The Author(s)Objectives: The underlying mechanisms for the development of chronic thromboembolic pulmonary hypertension and prognostic biomarkers are not clear yet. Thus, our aim is to assess and identify new biomarkers for the expression of 84 key genes linked to angiogenesis. Methods: Patients who had levels more than 1000 dynes·sec·cm−5 were included in the test group, and the other patients were included in the control group. Twelve specimens were taken from the patients. RT2 Profiler PCR Array (Qiagen) was used to quantify the expression of the 84 key genes. Results: Eight patients (6 male, 2 female, median age 54.4 ± 13.1 years) who underwent pulmonary endarterectomy were included. Pulmonary vascular resistance improved significantly from 811 ± 390 dyn/s/cm−5 to 413.3 ± 144.9 dyn/s/cm−5 (P .005) after surgery. Median length of hospital stay was 11.62 ± 2.97 days. The test group had a distinct pattern of impaired angiogenic and antiangiogenic genes. The expression levels of TGFA, TGFB1, THBS2, THBS1, TGFBR1, SERPINE1, SERPINF1, TGFB2, TIMP2, VEGFC, IFNA1, TNF, CXCL10, NOS3, IGF1, and MMP14 were downregulated in the specimens from the patients who had higher pulmonary vascular resistance values, whereas some genes, including PDGFA, showed upregulation that was statistically nonsignificant in the same group. Conclusions: These results can lead to the development of new markers that could predict adverse outcomes of patients with CTEPH. Identification of new markers that are related to worse outcomes would enable screening patients for early diagnosis and treatment.Publication Metadata only Timik patolojilerde cerrahi yaklaşım(2022-05-24) ERMERAK, NEZİH ONUR; YILDIZELİ, BEDRETTİN; LAÇİN, TUNÇ; Paşayev J., ASLAN S., TİRYAKİ G. G., Ertan R., Atasi M. K., ERMERAK N. O., YILDIZELİ B., LAÇİN T.Publication Metadata only Splenosis(2023-10-19) LAÇİN, TUNÇ; ERMERAK, NEZİH ONUR; Paşayev J., Ertan R., TİRYAKİ G. G., Atasi M. K., Önen H. U., Emran M., ASLAN S., LAÇİN T., ERMERAK N. O.Publication Metadata only Awake minimally invasive repair of pectus carinatum patients: results of 14 patients -first report in the literature(2023-06-22) ERMERAK, NEZİH ONUR; LAÇİN, TUNÇ; YILDIZELİ, BEDRETTİN; ERMERAK N. O., Ertan R., Paşayev J., YARBİL A., SEMERKANT T., LAÇİN T., YILDIZELİ B.